CLDX News and Press, Celldex Therapeutics Inc. From 05/09/24

2024-05-09 23:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 18:15:02 ET Guggenheim analyst issues UNDERPERFORM recommendation for CLDX on May 7, 2024 04:00PM ET. The previous analyst recommendation was Underperform. CLDX was trading at $42.21 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-07 18:15:02 ET H.C. Wainwright analyst issues BUY recommendation for CLDX on May 7, 2024 04:00PM ET. The previous analyst recommendation was Buy. CLDX was trading at $42.21 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-05-06 16:41:45 ET More on Celldex Celldex prices $400.4M stock offering Celldex GAAP EPS of -$0.83 misses by $0.09, revenue of $4.13M beats by $3.27M Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial in...

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Ph...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-04-20 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CInd...

2024-04-10 12:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...